United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $238.81, for a total transaction of $859,716.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $31,045.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Price Performance
United Therapeutics stock opened at $233.85 on Friday. The stock has a 50-day moving average price of $233.74 and a two-hundred day moving average price of $228.81. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54. The company has a market capitalization of $11.00 billion, a PE ratio of 11.79 and a beta of 0.52. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $4.28 by $0.08. The company had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. United Therapeutics’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.67 earnings per share. Analysts expect that United Therapeutics Co. will post 23.45 EPS for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Analysis on United Therapeutics
Hedge Funds Weigh In On United Therapeutics
Hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new stake in United Therapeutics in the fourth quarter valued at approximately $100,519,000. Avidity Partners Management LP acquired a new position in shares of United Therapeutics in the 4th quarter worth approximately $52,158,000. Comerica Bank boosted its stake in shares of United Therapeutics by 2,697.2% in the 3rd quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock valued at $35,368,000 after purchasing an additional 150,989 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of United Therapeutics by 309.7% during the fourth quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock worth $29,501,000 after buying an additional 101,419 shares during the period. Finally, TD Asset Management Inc raised its stake in United Therapeutics by 1,066.4% during the fourth quarter. TD Asset Management Inc now owns 82,951 shares of the biotechnology company’s stock worth $18,240,000 after buying an additional 75,839 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also
- Five stocks we like better than United Therapeutics
- What is MarketRankā¢? How to Use it
- 3 Stocks Leading the U.S. Agriculture Comeback
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What Are Growth Stocks and Investing in Them
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.